[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:sickle-cell-disease":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":312,"states":321},"Sickle Cell Disease",148,122,[8,16,23,29,36,42,48,54,61,67,73,79,85,91,97,103,109,116,122,128,134,140,145,151,156,163,169,175,181,187,193,199,205,211,217,223,229,235,241,247,253,259,264,270,276,282,288,294,300,306],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT02675959","Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease",[12],"Phase 2","RECRUITING","2026-08-26T02:17:35.666428Z","2026-07-30T01:46:14.457868Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07599176","Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors",[20],"Phase 1\u002FPhase 2","2026-08-26T02:15:14.574786Z","2026-07-19T19:36:05.076207Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06481306","A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease",[20],"2026-08-26T02:16:38.053590Z","2026-07-19T19:36:05.036036Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT03279094","Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease",[33],"Phase 1","2026-08-26T02:18:26.932189Z","2026-05-13T02:55:06.120905Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07369024","Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults",[12],"2026-08-26T02:19:19.162260Z","2026-05-05T02:47:14.264828Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT04156893","RH Genotype Matched RBC Transfusions",[20],"2026-08-26T02:19:13.549512Z","2026-05-05T02:43:29.739212Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06725550","Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0",[],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:29.587083Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT06609226","A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia",[58],"Phase 3","2026-08-26T02:17:50.500039Z","2026-05-05T02:43:29.465863Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT04008368","Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels",[20],"2026-08-26T02:16:59.895916Z","2026-05-05T02:43:29.409863Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07224360","Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)",[12],"2026-08-26T02:15:29.632183Z","2026-05-05T02:43:29.380541Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06374238","Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain",[],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.183213Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06016634","Alendronate for Osteonecrosis in Adults With Sickle Cell Disease",[12],"2026-08-26T02:17:54.420226Z","2026-05-05T02:43:29.043281Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT03587272","Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease",[12],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.967153Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07090668","Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease",[],"2026-08-26T02:16:21.385056Z","2026-05-05T02:43:28.883757Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05378555","Oral Ketamine for Treatment of Vaso-Occlusive Pain",[58],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:28.881497Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06439082","A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg\u002Fkg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)",[58],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:28.872801Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":114,"content_modified":115},"NCT05431088","A Phase 2\u002F3 Study in Adult and Adolescent Participants With SCD",[113],"Phase 2\u002FPhase 3","2026-08-26T02:17:39.048487Z","2026-05-05T02:43:28.840564Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT07226219","Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease",[33],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:28.708000Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07222475","Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease",[],"2026-08-26T02:19:22.562392Z","2026-05-05T02:43:28.677026Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT06975865","The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease",[58],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:28.623316Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT06290401","A Socio-ecological Approach for Improving Self-management in Adolescents With SCD",[12],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:28.559816Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":138,"content_modified":144},"NCT06506461","Gene Editing For Sickle Cell Disease",[33],"2026-05-05T02:43:28.559743Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT06699849","Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis",[12],"2026-08-26T02:19:25.538428Z","2026-05-05T02:43:28.487776Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":149,"content_modified":155},"NCT06612268","A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease",[58],"2026-05-05T02:43:28.344017Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":161,"content_modified":162},"NCT04657822","Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study",[160],"Phase 4","2026-08-26T02:15:09.079045Z","2026-05-05T02:43:28.303973Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT04055818","A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease",[33],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:28.184866Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT05685368","Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease",[20],"2026-08-26T02:17:20.511551Z","2026-05-05T02:43:28.175297Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT06184126","Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises",[],"2026-08-26T02:17:03.534765Z","2026-05-05T02:43:28.174180Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06770010","Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease",[],"2026-08-26T02:16:01.910993Z","2026-05-05T02:43:28.125977Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT04819841","Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease",[20],"2026-08-26T02:15:45.413021Z","2026-05-05T02:43:27.946550Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT06665997","Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease",[160],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:27.923139Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT06546670","A Phase I\u002FII Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease",[20],"2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.747349Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT06555939","Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease",[],"2026-08-26T02:15:51.395565Z","2026-05-05T02:43:27.732507Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT06635902","Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease",[12],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:27.611796Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT07442851","SickleFit Randomized Control Trial",[],"2026-08-26T02:16:11.347936Z","2026-05-05T02:43:27.606512Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT06919224","Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease",[],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:27.590577Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT01245179","Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease",[33],"2026-08-26T02:18:02.701182Z","2026-05-05T02:43:27.577119Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT06358638","Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody",[12],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.504692Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT07252050","Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease",[20],"2026-08-26T02:18:45.196599Z","2026-05-05T02:43:27.490694Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT07015684","131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)",[33],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:27.446315Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT02447874","Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease",[20],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:27.405925Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":245,"content_modified":263},"NCT05099874","Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease",[],"2026-05-05T02:43:27.404005Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":268,"content_modified":269},"NCT05373771","Sickle Cell Improvement: Enhancing Care in the Emergency Department",[],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:27.259698Z",{"nct_id":271,"title":272,"phases":273,"status":13,"updated_at":274,"content_modified":275},"NCT07023666","Early Screening and Treatment of Heart Complication in Sickle Cell Disease",[12],"2026-08-26T02:15:42.447052Z","2026-05-05T02:43:27.101969Z",{"nct_id":277,"title":278,"phases":279,"status":13,"updated_at":280,"content_modified":281},"NCT05640271","Tocilizumab for Acute Chest Syndrome",[12],"2026-08-26T02:15:49.658025Z","2026-05-05T02:43:26.955111Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":286,"content_modified":287},"NCT06647979","Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies",[33],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:26.921831Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":292,"content_modified":293},"NCT07187973","A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)",[33],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:26.918577Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":298,"content_modified":299},"NCT05477563","Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease",[58],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:26.772734Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":304,"content_modified":305},"NCT03121001","Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease",[12],"2026-08-26T02:17:11.311767Z","2026-05-05T02:43:26.681566Z",{"nct_id":307,"title":308,"phases":309,"status":13,"updated_at":310,"content_modified":311},"NCT04484272","A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease",[],"2026-08-03T02:28:34.088585Z","2026-05-05T02:35:31.685674Z",[313,317],{"biomarker":314,"count":315,"slug":316},"Hemoglobin",4,"hemoglobin",{"biomarker":318,"count":319,"slug":320},"Hemoglobin S",3,"hemoglobin-s",[322,326,330,333,336,340,343,346,350,353,357,361,365,369,372,376,380,384,388,391,395,398,402,405],{"state":323,"count":324,"slug":325},"Georgia",28,"georgia",{"state":327,"count":328,"slug":329},"Maryland",26,"maryland",{"state":331,"count":328,"slug":332},"Pennsylvania","pennsylvania",{"state":334,"count":328,"slug":335},"Tennessee","tennessee",{"state":337,"count":338,"slug":339},"California",25,"california",{"state":341,"count":338,"slug":342},"New York","new-york",{"state":344,"count":338,"slug":345},"Ohio","ohio",{"state":347,"count":348,"slug":349},"Illinois",23,"illinois",{"state":351,"count":348,"slug":352},"North Carolina","north-carolina",{"state":354,"count":355,"slug":356},"Alabama",19,"alabama",{"state":358,"count":359,"slug":360},"Texas",18,"texas",{"state":362,"count":363,"slug":364},"Massachusetts",17,"massachusetts",{"state":366,"count":367,"slug":368},"District of Columbia",15,"district-of-columbia",{"state":370,"count":367,"slug":371},"Florida","florida",{"state":373,"count":374,"slug":375},"Missouri",14,"missouri",{"state":377,"count":378,"slug":379},"Virginia",12,"virginia",{"state":381,"count":382,"slug":383},"Connecticut",10,"connecticut",{"state":385,"count":386,"slug":387},"Michigan",9,"michigan",{"state":389,"count":386,"slug":390},"South Carolina","south-carolina",{"state":392,"count":393,"slug":394},"Louisiana",8,"louisiana",{"state":396,"count":393,"slug":397},"New Jersey","new-jersey",{"state":399,"count":400,"slug":401},"Minnesota",6,"minnesota",{"state":403,"count":400,"slug":404},"Mississippi","mississippi",{"state":406,"count":407,"slug":408},"Arizona",5,"arizona"]